Myasthenia	myasthenia	O	DISEASE	OTHERS	I
gravis	gravis	O	DISEASE	OTHERS	I
caused	caused	O	O	O	O
by	by	O	O	O	O
penicillamine	penicillamine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
chloroquine	chloroquine	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
for	for	O	O	O	O
rheumatoid	rheumatoid	O	DISEASE	OTHERS	I
arthritis	arthritis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
have	have	O	O	O	O
described	described	O	O	O	O
a	a	O	O	O	O
unique	unique	O	O	O	O
patient	patient	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
reversible	reversible	O	O	O	O
and	and	O	O	O	O
dose-related	dose-related	O	O	O	O
myasthenia	myasthenia	O	DISEASE	OTHERS	I
gravis	gravis	O	DISEASE	OTHERS	I
after	after	O	O	O	O
penicillamine	penicillamine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
chloroquine	chloroquine	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
for	for	O	O	O	O
rheumatoid	rheumatoid	O	DISEASE	OTHERS	I
arthritis	arthritis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Although	although	O	O	O	O
acetylcholine	acetylcholine	CHEMICALS	O	OTHERS	I
receptor	receptor	O	O	O	O
antibodies	antibodies	O	O	O	O
were	were	O	O	O	O
not	not	O	O	O	O
detectable	detectable	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
time	time	O	O	O	O
course	course	O	O	O	O
was	was	O	O	O	O
consistent	consistent	O	O	O	O
with	with	O	O	O	O
an	an	O	O	O	O
autoimmune	autoimmune	O	O	O	O
process	process	O	O	O	O
.	.	O	O	O	O

